BACKGROUND Long-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed. METHODS We investigated the role of melanoma-associated antibodies as predictive markers for CI therapy in two independent cohorts. In cohort 1, a prospective study, we measured specific antibodies before treatment, after one week and after six to nine weeks of treatment. Cohort 2 consisted of serum samples prior to CI therapy initiation. ELISA assays were performed to quantify specific IgG directed against melanocyte differentiation antigens tyrosinase-related proteins 1 and 2 (TRP1/TYRP1 and TRP2/TYRP2), glycoprotein 10...
Advanced melanoma is an aggressive cancer with a poor prognosis once disseminated to other organs. H...
Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not a...
Background.The identification of factors influencing ICI efficacy in cancer pts and the elaboration ...
BACKGROUND Long-term survival of stage IV melanoma patients has improved significantly with the dev...
BACKGROUND Long-term survival of stage IV melanoma patients has improved significantly with the d...
Checkpoint inhibitors have improved survival of metastatic melanoma. However, reliable biomarkers to...
Simple Summary Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced melanom...
Checkpoint inhibitors have improved survival of metastatic melanoma. However, reliable biomarkers to...
Background Immune checkpoint inhibitors (ICIs) have changed the clinical management ...
Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have shown impressive thera...
PURPOSE: Immunotherapy using immune checkpoint inhibitors (ICI) has revolutionized cancer treatment ...
Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against...
The recent emergence of cancer immunotherapies initiated a significant shift in the clinical managem...
Immune checkpoint inhibitors (ICIs), which target CTLA-4 or PD-(L)1 molecules, have shown impressive...
BackgroundImmune checkpoint inhibition (ICI) with anti-CTLA-4 and/or anti-PD-1 antibodies is standar...
Advanced melanoma is an aggressive cancer with a poor prognosis once disseminated to other organs. H...
Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not a...
Background.The identification of factors influencing ICI efficacy in cancer pts and the elaboration ...
BACKGROUND Long-term survival of stage IV melanoma patients has improved significantly with the dev...
BACKGROUND Long-term survival of stage IV melanoma patients has improved significantly with the d...
Checkpoint inhibitors have improved survival of metastatic melanoma. However, reliable biomarkers to...
Simple Summary Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced melanom...
Checkpoint inhibitors have improved survival of metastatic melanoma. However, reliable biomarkers to...
Background Immune checkpoint inhibitors (ICIs) have changed the clinical management ...
Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have shown impressive thera...
PURPOSE: Immunotherapy using immune checkpoint inhibitors (ICI) has revolutionized cancer treatment ...
Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against...
The recent emergence of cancer immunotherapies initiated a significant shift in the clinical managem...
Immune checkpoint inhibitors (ICIs), which target CTLA-4 or PD-(L)1 molecules, have shown impressive...
BackgroundImmune checkpoint inhibition (ICI) with anti-CTLA-4 and/or anti-PD-1 antibodies is standar...
Advanced melanoma is an aggressive cancer with a poor prognosis once disseminated to other organs. H...
Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not a...
Background.The identification of factors influencing ICI efficacy in cancer pts and the elaboration ...